Speakers: John P. Feldman Kevin M. Madagan

Event Type: Webinar

Start Date/Time:
7 October 2015
End Date/Time:
7 October 2015

This webcast will focus on the legal liability and responsibility of a drug or device company incorporating consumer review—or any user-generated content (UGC)—functionality on a website or within social media channels. In particular, it will focus on the company's responsibility and liability when consumers post off-label use statements or describe adverse events in this context.

During this webcast, attendees will learn about the Communications Decency Act (CDA), a federal law that makes an Internet service provider immune from UGC on its service under many circumstances, as long as the provider is not controlling the statements to such a degree it makes them its own. FDA policy and statements regarding the CDA and social media will be explored as well as the interplay between the CDA and the Food, Drug, and Cosmetic Act.

Learning Levels: Basic and Intermediate

  • Articulate the scope and intent of the Communications Decency Act
  • Understand the guidelines for hosting UGC content in a promotional website forum
  • Differentiate between acceptable moderation and hosting of UGC and publication of speech that falls outside CDA immunity.  

Who Should Attend

  • Regulatory professionals
  • Marketing and sales professionals
  • Attorneys
  • Compliance specialists

To view the OnDemand content visit, raps.personifycloud.com.